Search Results
May 06, 2026, 08:30 ET IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
May 06, 2026, 08:02 ET The Foundation Assar Gabrielsson Prize recipients 2026 awarded
approaches, with the overarching goal of translating discoveries into patient benefit. She defended her thesis with a focus on KRAS-mutated non-small lung cancer in November 2025," says Professor Eva Forssell-Aronsson.Assar Gabrielsson was one of the founders of Volvo. In accordance with his wishes,
More news about: AB Volvo
May 06, 2026, 08:00 ET Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
ATNM-400, Actinium's first-in-class Actinium-225 (225Ac) antibody radioconjugate, demonstrating its potential in prostate cancer and non-small cell lung cancer (NSCLC), as well as a third poster presenting preclinical radiochemistry data on chelator-to-antibody ratio (CAR) optimization that underpins
More news about: Actinium Pharmaceuticals, Inc.
May 06, 2026, 08:00 ET Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
timeline.About ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed
More news about: Nuvation Bio Inc.
May 06, 2026, 07:00 ET (E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
indications, with a Phase 3 clinical program in acute myeloid leukemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and
More news about: Racura Oncology
May 05, 2026, 17:00 ET CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
with Duchenne muscular dystrophy ("DMD"). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. Discussions with the FDA are underway regarding the study results and remaining requirements for approval.During the first quarter of
More news about: Cumberland Pharmaceuticals Inc.
May 05, 2026, 16:05 ET TransMedics Reports First Quarter 2026 Financial Results
Society of Heart and Lung Transplantation (ISHLT) 46th Annual Meeting & Scientific Session in Toronto; unveiled new Controlled Hypothermic Organ Preservation System ("CHOPS") aimed at facilitating enrollment in control arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung clinical trialsEntered
More news about: TransMedics Group, Inc.
May 05, 2026, 16:01 ET Rigel Reports First Quarter 2026 Financial Results
that over 229,000 adults in the U.S. will be diagnosed with lung cancer in 2026. Lung cancer is the leading cause of cancer death in the U.S., with non-small cell lung cancer (NSCLC) being the most common type accounting for 77% of all lung cancer diagnoses.2 RET fusions are implicated in
More news about: Rigel Pharmaceuticals, Inc.
May 05, 2026, 14:54 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
May 05, 2026, 08:44 ET Free Asbestos Screening Goes Mobile: CARDs Outreach and Education Available Across the Nation
10-August 13 | Hilton Garden Inn 3720 North Reserve St.The clinics offer comprehensive screening, including chest X-rays, blood testing, lung function testing, and a detailed exposure history, followed by consultation with CARD staff. Additional imaging may be recommended. Services are provided
More news about: Center for Asbestos Related Disease, Inc. (CARD)
May 05, 2026, 08:30 ET IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
May 05, 2026, 08:05 ET AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in
More news about: AbbVie
May 05, 2026, 07:00 ET Altesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations
utilization, and lung function.About Altesa BioSciences, Inc.Altesa BioSciences is a clinical-stage pharmaceutical company led by global experts in respiratory medicine and infectious diseases. We are dedicated to improving the lives of people with chronic lung diseases like
More news about: Altesa Biosciences Inc.
May 05, 2026, 06:00 ET IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Phase 1/2 trial in MTAP-deleted urothelial and lung cancers.Other programsIDE574 (KAT6/7): achieved FPI in Phase 1 dose escalation trial of IDE574 in solid tumors including breast, prostate, colorectal and lung cancer. IDE574 is a selective, equipotent dual
More news about: IDEAYA Biosciences, Inc.
May 05, 2026, 05:04 ET World Asthma Day Highlights Urgent Need for Education, Support and Advocacy to Improve the Lives of People with Asthma
Lung.org/asthma-awareness.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
May 05, 2026, 03:48 ET GIGABYTE giành Giải thưởng Thiết kế Red Dot cho dòng sản phẩm AI
bị thiết kế tản nhiệt WINDFORCE Hyperburst hoàn toàn mới, dựa trên cấu trúc luồng kép đột phá cho phép luồng gió thâm nhập vào cả hai mặt của tấm ốp lưng, giúp nâng cao hiệu quả tản nhiệt. Đáng chú ý, Quạt Overdrive, với đường cong quạt độc lập, sẽ được kích hoạt khi thực hiện khối lượng công việc cường
More news about: GIGABYTE
May 04, 2026, 16:12 ET Brayton Purcell LLP announces $17,450,000 Verdict In The First Colorado Artificial Stone Countertop Fabrication Silicosis Case
fabrication workers developing fatal artificial stone accelerated silicosis and other silica-diseases such as chronic kidney disease, autoimmune disease, and lung cancer from just a few years of exposure to uniquely toxic artificial stone. The Jordan verdict is the second jury to find that crystalline
More news about: Brayton Purcell LLP
May 04, 2026, 16:10 ET Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
event.About ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed
More news about: Nuvation Bio Inc.
May 04, 2026, 08:09 ET Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting
non-small cell lung cancer (NSCLC)SessionPoster Session - Lung Cancer-Non-Small
More news about: Iterion Therapeutics
May 04, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.Patients are encouraged
More news about: Insmed Incorporated
May 01, 2026, 09:15 ET Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
May 01, 2026, 09:00 ET Allergy & Asthma Network Introduces PSA Campaign "Control Your Asthma" to Improve Outcomes Nationwide
to empowering patients, advancing health equity, and ensuring that every person with asthma has the knowledge and support needed to achieve optimal lung health."Asthma control should never be guesswork," said Lynda Mitchell, CEO of Allergy & Asthma Network. "Our PSAs give families the tools
More news about: Allergy & Asthma Network
May 01, 2026, 08:37 ET Researchers from Incheon National University Spotlight Next-Generation EV Diagnostics
screening."Clinical studies cited in the review suggest these tools can distinguish healthy individuals from patients with pancreatic cancer, cholangiocarcinoma, and lung adenocarcinoma by identifying rare tumor-derived EVs in plasma. Beyond cancer, the same principles may help track cardiovascular disease, neurodegenerative
More news about: Incheon National University
Apr 30, 2026, 20:17 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 30, 2026, 19:02 ET /C O R R E C T I O N -- Amgen/
National Medical Products Administration (NMPA) granted a conditional approval to IMDELLTRA for the treatment of third-line extensive stage small cell lung cancer (SCLC).The Company is advancing a comprehensive, global clinical development program across extensive-stage (ES) and limited-stage (LS)
More news about: Amgen